trial · primary record
ETX-929 dose escalation
Metastatic Colorectal Cancer (CRC)
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 320 |
| Primary completion | 2029-04-30 |
| Primary endpoint | Evaluate Safety and Tolerability of ETX-929 monotherapy in Part A and ETX-929 plus cetuximab combination therapy in Part B |
| Registry ID | NCT07912593 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:59:24.956Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07912593
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.